Healthcare >> Analyst Interviews >> May 8, 2002

Investing In Biotechnology: Mary Gray – Federated Kaufmann Fund

MARY ANN GRAY has been with the Federated Kaufmann Fund for the past two years, focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell side Biotechnology Analyst for nine years with Kidder Peabody; Dillon, Read; and Raymond James. Earlier in her career, Dr. Gray managed preclinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute and worked in a hospital laboratory. She did postdoctoral work at Northwestern University Medical School and Yale University School of Medicine. She held scientific positions at Schering-Plough and NeoRx. Dr. Gray has a PhD in Pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer. Profile
TWST: What is the Federated Kaufmann Fund focused on today within

the biotech and healthcare life sciences area?

Dr. Gray: Today, in terms of the whole fund, health care is one

of the largest